Skip to content

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Shannon L. Maude, Theodore Willis Laetsch, Jochen Buechner, Susana Rives, Michael Joseph Boyer, Henrique Neves da Silva Bittencourt, Peter Bader, Michael R. Verneris, Heather Emily Stefanski, Gary D. Myers, Muna D. Qayed, Barbara De Moerloose, Hidefumi Hiramatsu, Krysta D. Schlis, Kara Lynn Davis, Paul L. Martin, Eneida R. Nemecek, Gregory Anthony Yanik, Christina Peters, André Baruchel, Nicolas Boissel, Francoise Marie Mechinaud, Adriana Balduzzi, Joerg Krueger, Carl H. June, Bruce L. Levine, Patricia Ann Wood, Tetiana Taran, Mimi Leung, Karen T. Mueller, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Michael A. Pulsipher, Stephan A. Grupp

New England Journal of Medicine · 2018 · 5,900 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M. J., Bittencourt, H. N. da S., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M. D., Moerloose, B. D., Hiramatsu, H., Schlis, K. D., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., … Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439–448. https://doi.org/10.1056/nejmoa1709866

In text: (Maude et al., 2018)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).

  1. Control of Regulatory T Cell Development by the Transcription Factor Foxp32003
  2. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017
  3. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia2014
  4. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma2018
  5. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity2009

Metadata from OpenAlex (CC0). Citations are generated from the published record.